SOC Telemed Reports Second Quarter 2021 Financial and Operating Results
SOC Telemed (NASDAQ: TLMD) reported strong growth in Q2 2021, with total consults reaching 130,214, a 98% year-over-year increase. Key highlights include a successful telePsychiatry expansion with UnityPoint Health, contributing significant cost savings. Revenue totaled $25 million, up 84%, but a net loss of $14.5 million was noted. The company revised its 2021 revenue guidance to $90-$92 million, down from the previous $97-$103 million, citing impacts from the Delta variant and strategic shifts. As of June 30, 2021, SOC had $50 million in cash.
- Total system-wide consults increased by 98% year-over-year.
- Revenue rose to $25 million, an 84% increase compared to Q2 2020.
- Successful expansion of telePsychiatry service with UnityPoint Health, leading to significant cost savings.
- Late-stage pipeline grew by 30% since Q1 2021.
- Net loss increased to $(14.5) million from $(8.2) million year-over-year.
- Revised 2021 revenue guidance decreased to $90-$92 million, down from $97-$103 million.
- GAAP gross margin slightly declined to 32% compared to 33% in Q2 2020.
RESTON, Va., Aug. 12, 2021 /PRNewswire/ -- SOC Telemed, Inc., (NASDAQ: TLMD), the largest national provider of acute care telemedicine, today announced its financial and operating results for the second quarter ending June 30, 2021.
"Our second quarter results reflect strong growth driven by a return to pre-COVID consult volumes in our telePsychiatry service line and a near return in our teleNeurology service line," said John Kalix, Chief Executive Officer of SOC Telemed. "Our late stage pipeline grew
He further stated, "The ability to provide a comprehensive offering of clinical services combined with the Telemed IQ platform positions SOC Telemed to help solve our client's friction points around access to specialty physicians, network integrity, and optimization of clinician resources. As the largest acute telemedicine provider, we are well positioned to be the provider of choice as hospitals consolidate to a single vendor."
Second Quarter and Recent Highlights
- Announced a multi-site telePsychiatry service line expansion with UnityPoint Health for the Des Moines, Iowa, and Cedar Rapids, Iowa, markets, expected to go live in 2H21. UnityPoint Health's multi-site expansion was driven by the success case developed at UnityPoint Health Allen Hospital, which reduced average length of stay (ALOS) by approximately 12 hours, reduced its readmission rate by
4% , and avoided more than$1.7 million in annualized boarding costs, leading to an annual ROI of281% - In May, we announced an expanded partnership with SCP Health (SCP). Under the multi-year agreement, SOC Telemed will provide the Telemed IQ platform to help accelerate and expand SCP's telehealth capabilities across the country
- In April, Bon Secours Mercy – Lourdes Hospital implemented the teleICU service line, and Davis Regional Medical Center implemented the teleNeurology and teleStroke service lines
Operating Metrics Summary
Operational performance metrics for the three months ended June 30, 2021, compared to the three months ended June 30, 2020. We present consults on a pro forma basis (i.e., giving retroactive effect to the Access Physicians acquisition to January 1, 2020) to provide investors with insight into how management views the performance of the combined business period over period.
- Total system-wide consults were 130,214 compared to 65,690, up
98% year over year, and up49% year over year on a pro forma basis - Stand-alone SOC core consults totaled 37,817 compared to 30,213, up
25% on a year over year basis. TelePsychiatry volumes recovered to pre-COVID levels faster than expected, and the teleNeurology service line experienced significant volume increases - Access Physicians contributed 31,700 core consults, up
47% on a year over year basis - System-wide revenue per core consult totaled
$339 compared to$349 , down3% , primarily driven by the addition of Access Physicians, as revenue per core consult at Access Physicians is historically lower than revenue per core consult at legacy SOC. The average revenue per core consult is also impacted by duration of each consult, which varies widely between service lines - Stand-alone SOC revenue per core consult was
$417 versus$429 , as the volume recovery in telePsychiatry and teleNeurology narrowed the gap associated with minimum consult thresholds in client contracts - Access Physicians revenue per core consult was
$245 versus$237 , up3% year over year, driven by service line volume mix - Implementations totaled 74 compared to 80, with Access Physicians contributing 11 implementations
- Stand-alone SOC services per facility totaled 2.1 compared to 1.9, demonstrating the continued opportunity to expand across both service lines and sites with existing customers
- Total facilities serviced were 1,028 compared to 847 a year ago, up
21% on a year over year basis. The 1,028 facilities serviced includes 179 facilities serviced by Access Physicians
Financial Results Summary
Financial performance for the three months ended June 30, 2021, compared to the three months ended June 30, 2020.
- Bookings totaled
$6.7 million , up136% - Revenue totaled
$25.0 million compared to$13.6 million , up84% - Access Physicians contributed
$8.4 million of revenue - GAAP gross profit totaled
$8.0 million compared to$4.5 million - Adjusted gross profit (non-GAAP) totaled
$9.3 million compared to$5.5 million - GAAP gross margin was
32% compared to33% - Adjusted gross margin (non-GAAP) was
37% compared to40% . Results were negatively impacted primarily by an increase in physician incentive payments related to the rapid increase and volatility of consult demand - Net loss totaled
$(14.5) million compared to a net loss of$(8.2) million - Adjusted EBITDA loss totaled
$(5.4) million compared to$(1.6) million
Balance Sheet
As of June 30, 2021, the Company had cash and cash equivalents of
In June 2021, SOC Telemed completed an underwritten follow-on public offering of 9.2 million shares generating net proceeds of approximately
2021 Financial Outlook
For the full year 2021, SOC Telemed is providing the following revised financial guidance:
- GAAP Revenue is expected to be in the range of
$90 million to$92 million , with approximately30% expected to be attributed to Access Physicians - Primary drivers of the guidance revision include impacts from the Delta variant of COVID-19, specifically on increased pressure on hospital emergency departments, and a change in go-to-market strategy around hardware sales related to the integration of Access Physicians
- The previous GAAP revenue guidance range was
$97 million to$103 million , with approximately30% to35% expected to be attributed to Access Physicians - Adjusted gross margin is expected to be in the range of
37.0% and40.0% - Adjusted EBITDA is expected to be in the range of
$(22.0) million to$(25.0) million
These statements are forward-looking and actual results may differ materially. Please refer to the Forward-Looking Statements safe harbor below for information on the factors that could cause our actual results to differ materially from these forward-looking statements.
SOC Telemed has not reconciled its expectations as to Adjusted Gross Margin and Adjusted EBITDA to the most comparable GAAP measures because certain items are out of its control or cannot be reasonably calculated or predicted at this time without unreasonable efforts. Accordingly, a reconciliation for forward-looking Adjusted Gross Margin and Adjusted EBITDA is not available without unreasonable effort.
Upcoming Conferences and Investor Events
Wells Fargo Virtual Healthcare Conference, September 9 – 10, 2021
Baird 2021 Global Healthcare Conference, September 14 - 15, 2021
Conference Call Details
The second quarter 2021 earnings conference call and webcast will be held on August 12, 2021, at 5:00 p.m. ET. The conference call can be accessed by dialing, either:
Domestic: (877) 870-4263
International: (412) 317-0790
Passcode: reference "SOC Telemed call"
A live audio webcast will be available on the Investor Relations section of the Company website at investors.soctelemed.com. A webcast replay will be available for on-demand listening shortly after the completion of the call at the same web link.
About SOC Telemed
SOC Telemed (NASDAQ: TLMD, "SOC") is the leading national provider of acute telemedicine technology and solutions to hospitals, health systems, post-acute providers, physician networks, and value-based care organizations since 2004. Built on proven and scalable infrastructure as an enterprise-wide solution, SOC's technology platform, Telemed IQ, rapidly deploys and seamlessly optimizes telemedicine programs across the continuum of care. SOC provides a supportive and dedicated partner presence, virtually delivering patient care through teleNeurology, telePsychiatry, teleCritical Care, telePulmonology, teleCardiology, teleInfectious Disease, teleNephrology, teleMaternal-Fetal Medicine and other service lines, enabling healthcare organizations to build sustainable telemedicine programs across clinical specialties. SOC enables organizations to enrich their care models and touch more lives by supplying healthcare teams with industry-leading solutions that drive improved clinical care, patient outcomes, and organizational health. The company was the first provider of acute clinical telemedicine services to earn The Joint Commission's Gold Seal of Approval and has maintained that accreditation every year since inception. For more information, visit www.soctelemed.com.
Forward-Looking Statements
This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. In some cases, you can identify these forward-looking statements by the use of terms such as "expect," "will," "continue," or similar expressions, and variations or negatives of these words, but the absence of these words does not mean that a statement is not forward-looking. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including, but not limited to: the statements under "2021 Outlook," including expectations relating to bookings and revenue; statements regarding relationships with customers and business momentum; statements regarding the expected benefits of the acquisition of Access Physicians (including anticipated synergies, projected financial information and future opportunities); and any other statements of expectation or belief. These statements are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from results expressed or implied in this press release. Such risk factors include, but are not limited to, those related to: the current and future impact of the COVID-19 pandemic on SOC Telemed's business and industry; continued difficulties in the integration of Access Physicians; the effects of competition on the future business of SOC Telemed; uncertainty regarding the demand for and market utilization of its solution; returns on investments in its business; the ability to maintain customer relationships; difficulties maintaining and expanding its network of qualified physicians and other provider specialists; disruptions in SOC Telemed's relationships with affiliated professional entities or third party suppliers or service providers; general business and economic conditions; the ability of SOC Telemed to successfully execute strategic plans; the timing and market acceptance of new solutions or success of new enhancements, features modifications to existing solutions and the degree to which they gain acceptance. Additional information concerning these and other risk factors is contained in the Risk Factors section of SOC Telemed's most recent annual report on Form 10-K. Additional information will be made available in SOC Telemed's quarterly report on Form 10-Q for the three months ended June 30, 2021, and other filings and reports that SOC Telemed may file from time to time with the SEC. SOC Telemed assumes no obligation, and does not intend, to update these forward-looking statements as a result of future events or developments.
Use of Non-GAAP Financial Information
We believe that, in addition to our financial results determined in accordance with GAAP, adjusted gross profit (non-GAAP), adjusted gross margin (non-GAAP), and adjusted EBITDA, all of which are non-GAAP financial measures, are useful in evaluating our business, results of operations, and financial condition. However, our use of the terms adjusted gross profit, adjusted gross margin and adjusted EBITDA may vary from that of others in our industry. Adjusted gross profit, adjusted gross margin and adjusted EBITDA should not be considered as an alternative to gross profit, net loss, net loss per share or any other performance measures derived in accordance with GAAP as measures of performance. Adjusted gross profit, adjusted gross margin and adjusted EBITDA have important limitations as analytical tools and you should not consider them in isolation or as a substitute for analysis of our results as reported under GAAP. Some of these limitations are:
- adjusted EBITDA does not reflect the significant interest expense on our debt;
- although depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and adjusted gross profit, adjusted gross margin and adjusted EBITDA do not reflect any expenditures for such replacements; and
- other companies in our industry may calculate these financial measures differently than we do, limiting their usefulness as comparative measures.
We compensate for these limitations by using these non-GAAP financial measures along with other comparative tools, together with GAAP measurements, to assist in the evaluation of operating performance. Such GAAP measurements include gross profit, net loss, net loss per share and other performance measures. In evaluating these financial measures, you should be aware that in the future we may incur expenses similar to those eliminated in this presentation. Our presentation of non-GAAP financial measures should not be construed as an inference that our future results will be unaffected by unusual or nonrecurring items. When evaluating our performance, you should consider these non-GAAP financial measures alongside other financial performance measures, including the most directly comparable GAAP measures set forth in the reconciliation tables below and our other GAAP results.
Our non-GAAP financial measures are described as follows:
Adjusted gross profit and adjusted gross margin. Adjusted gross profit is defined as revenues less cost of revenues plus depreciation and amortization plus equipment leasing costs plus stock-based compensation. Adjusted gross margin is adjusted gross profit divided by revenues.
Adjusted EBITDA. Adjusted EBITDA is defined as net income (loss) before interest, taxes, depreciation and amortization, stock-based compensation, gain on contingent shares issuance liabilities, loss on puttable option liabilities, gain on change in fair value of contingent consideration, and integration, acquisition, transaction and executive severance costs.
Readers are encouraged to review the reconciliation of our non-GAAP financial measures to the comparable GAAP results, which is attached to this earnings release and which can be found on SOC Telemed's investor relations page of its website at: investors.soctelemed.com.
Operating Metrics
Because our consultation fee revenue generally increases as the number of visits increase, we believe the number of consultations provides investors with useful information on period-to-period performance as evaluated by management and as a comparison to our past financial performance. We define core consultations as consultations utilizing our 11 core services. Telemed IQ / other consultations are defined as consultations performed by other physician networks utilizing our technology platform, Telemed IQ. Pro forma consultations represent the number of total consultations as if Access Physicians had been acquired as of January 1, 2020.
Number of Consults | ||||||||||||||||||||||||||
Q1 2020 | Q2 2020 | Q3 2020 | Q4 2020 | Q1 2021 | Q2 2021 | |||||||||||||||||||||
Core | 36,347 | 30,213 | 32,126 | 30,920 | 31,447 | 37,817 | ||||||||||||||||||||
Access Physicians | - | - | - | - | 1,282 | 31,700 | ||||||||||||||||||||
Telemed IQ / Other | 30,649 | 35,477 | 47,800 | 57,292 | 62,636 | 60,697 | ||||||||||||||||||||
Total Consults | 66,996 | 65,690 | 79,926 | 88,212 | 95,365 | 130,214 | ||||||||||||||||||||
Number of Pro Forma Consults | ||||||||||||||||||||||||||
Q1 2020 | Q2 2020 | Q3 2020 | Q4 2020 | Q1 2021 | Q2 2021 | |||||||||||||||||||||
Core | 36,347 | 30,213 | 32,126 | 30,920 | 31,447 | 37,817 | ||||||||||||||||||||
Access Physicians | 20,067 | 21,577 | 26,357 | 30,925 | 33,399 | 31,700 | ||||||||||||||||||||
Telemed IQ | 31,175 | 35,777 | 48,085 | 57,642 | 63,001 | 60,697 | ||||||||||||||||||||
Total Consults | 87,589 | 87,567 | 106,568 | 119,487 | 127,847 | 130,214 | ||||||||||||||||||||
SOC Telemed, Inc. and Subsidiaries and Affiliates CONSOLIDATED BALANCE SHEETS (In thousands, except shares and per share amounts) (Unaudited) | |||
ASSETS |
|
| |
CURRENT ASSETS | |||
Cash and cash equivalents (from variable interest entities | $ 50,005 | $ 38,754 | |
Accounts receivable, net of allowance for doubtful accounts of | 14,438 | 8,721 | |
Inventory | 1,356 | - | |
Prepaid expenses and other current assets (from variable interest entities | 4,997 | 1,609 | |
Total current assets | 70,796 | 49,084 | |
Property and equipment, net | 3,970 | 4,092 | |
Capitalized software costs, net | 10,062 | 8,935 | |
Intangible assets, net | 46,204 | 5,988 | |
Goodwill | 155,647 | 16,281 | |
Deposits and other assets | 1,843 | 559 | |
Total assets | $ 288,522 | $ 84,939 | |
LIABILITIES AND STOCKHOLDERS' EQUITY | |||
Current liabilities | |||
Accounts payable (from variable interest entities | $ 8,271 | $ 2,809 | |
Accrued expenses (from variable interest entities | 11,221 | 8,293 | |
Deferred revenues | 531 | 610 | |
Capital lease obligations | 22 | - | |
Contingent consideration | 318 | - | |
Stock-based compensation liabilities | - | 4,228 | |
Total current liabilities | 20,363 | 15,940 | |
Deferred revenues | 1,012 | 923 | |
Capital lease obligations | 52 | - | |
Long term debt, net of unamortized discount and debt issuance costs | 73,563 | - | |
Contingent shares issuance liabilities | 6,806 | 12,450 | |
Other long-term liabilities (from variable interest entities | 560 | 560 | |
Total liabilities | $ 102,356 | $ 29,873 | |
COMMITMENTS AND CONTINGENCIES | |||
STOCKHOLDERS' EQUITY | |||
Class A common stock, | 10 | 8 | |
Preferred stock, | - | - | |
Additional paid-in capital | 449,428 | 291,277 | |
Accumulated deficit | (263,272) | (236,219) | |
Total stockholders' equity (deficit) | 186,166 | 55,066 | |
Total liabilities, contingently redeemable preferred | |||
$ 288,522 | $ 84,939 | ||
SOC Telemed, Inc. and Subsidiaries and Affiliates CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except shares and per share amounts) (Unaudited) | ||||||||||||||||
Three Months Ended | Six Months Ended | |||||||||||||||
2021 | 2020 | 2021 | 2020 | |||||||||||||
Revenues | $ | 24,960 | $ | 13,554 | $ | 39,781 | $ | 28,361 | ||||||||
Cost of revenues | 16,937 | 9,030 | 26,704 | 19,743 | ||||||||||||
Operating expenses | ||||||||||||||||
Selling, general and administrative | 22,479 | 9,753 | 43,740 | 18,274 | ||||||||||||
Changes in fair value of contingent consideration | (2,947) | - | (2,947) | - | ||||||||||||
Total operating expenses | 19,532 | 9,753 | 40,793 | 18,274 | ||||||||||||
Loss from operations | (11,509) | (5,229) | (27,716) | (9,656) | ||||||||||||
Other income (expense) | ||||||||||||||||
Gain on contingent shares issuance liabilities | 2,192 | - | 5,644 | - | ||||||||||||
Loss on puttable option liabilities | - | (96) | - | (105) | ||||||||||||
Interest expense | (3,123) | (2,836) | (3,272) | (5,616) | ||||||||||||
Interest expense – Related party | (2,001) | - | (2,026) | - | ||||||||||||
Total other income (expense) | (2,932) | (2,932) | 346 | (5,721) | ||||||||||||
Loss before income taxes | (14,441) | (8,161) | (27,370) | (15,377) | ||||||||||||
Income tax benefit (expense) | (17) | (2) | 317 | (3) | ||||||||||||
Net loss and comprehensive loss | $ | (14,458) | $ | (8,163) | $ | (27,053) | $ | (15,380) | ||||||||
Accretion of contingently redeemable preferred stock | - | (2,023) | - | (3,518) | ||||||||||||
Net loss attributable to common stockholders | $ | (14,458) | $ | (10,186) | $ | (27,053) | $ | (18,898) | ||||||||
Net loss per share attributable to common stockholders | ||||||||||||||||
Basic | $ | (0.16) | $ | (0.30) | $ | (0.32) | $ | (0.55) | ||||||||
Diluted | $ | (0.16) | $ | (0.30) | $ | (0.32) | $ | (0.55) | ||||||||
Weighted-average shares used to compute net loss per | ||||||||||||||||
Basic | 89,697,396 | 34,345,197 | 83,744,959 | 34,345,197 | ||||||||||||
Diluted | 89,697,396 | 34,345,197 | 83,744,959 | 34,345,197 | ||||||||||||
SOC Telemed, Inc. and Subsidiaries and Affiliates CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands) (Unaudited) | ||||||||
Six Months Ended | ||||||||
2021 | 2020 | |||||||
Cash flows from operating activities: | ||||||||
Net loss | $ | (27,053) | $ | (15,380) | ||||
Adjustments to reconcile net loss to net cash used in operating activities | ||||||||
Depreciation and amortization | 4,141 | 2,607 | ||||||
Stock-based compensation | 10,644 | 247 | ||||||
Change in fair value of contingent consideration | (2,947) | - | ||||||
Loss on puttable option liabilities | - | 105 | ||||||
(Gain) on contingent shares issuance liabilities | (5,644) | - | ||||||
Bad debt expense | 47 | 43 | ||||||
Paid-in kind interest on long-term debt | 203 | 1,527 | ||||||
Amortization of debt issuance costs and issuance discount | 3,403 | 710 | ||||||
Income tax benefit | (343) | - | ||||||
Change in assets and liabilities, net of acquisitions | ||||||||
Accounts receivable, net of allowance | (162) | 2,981 | ||||||
Prepaid expense and other current assets | (2,752) | (1,472) | ||||||
Inventory | 26 | - | ||||||
Deposits and other non-current assets | (999) | 11 | ||||||
Accounts payable | 2,647 | (921) | ||||||
Accrued expenses and other current liabilities | 742 | 2,334 | ||||||
Deferred revenues | 9 | 143 | ||||||
Net cash used in operating activities | (18,038) | (7,065) | ||||||
Cash flows from investing activities: | ||||||||
Capitalization of software development costs | (2,132) | (2,090) | ||||||
Purchase of property and equipment | (635) | (1,222) | ||||||
Acquisition of business, net of cash | (89,752) | - | ||||||
Net cash used in investing activities | (92,519) | (3,312) | ||||||
Cash flows from financing activities: | ||||||||
Principal payments under capital lease obligations | - | (45) | ||||||
Proceeds from long-term debt, net of discount | 83,219 | - | ||||||
Proceeds from Related-party – Unsecured subordinated promissory note | 11,500 | - | ||||||
Repayment of long-term debt | (10,795) | - | ||||||
Repayment of Related-party – Unsecured subordinated promissory note, net of | (13,703) | - | ||||||
Proceeds from exercise of stock options | 42 | - | ||||||
Issuance of contingently redeemable preferred stock | - | 10,938 | ||||||
Proceeds from issuance of Class A Common Stock, net of issuance costs | 51,545 | - | ||||||
Net cash provided by financing activities | 121,808 | 10,893 | ||||||
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS | 11,251 | 516 | ||||||
Cash and cash equivalents at beginning of the period | 38,754 | 4,541 | ||||||
Cash and cash equivalents at end of the period | $ | 50,005 | $ | 5,057 | ||||
SOC Telemed, Inc. and Subsidiaries and Affiliates RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (In thousands, except per share data) (Unaudited) | ||||||||||||||||||||||||||||||
Three Months Ended | Six Months Ended | Three Months Ended | Six Months Ended | |||||||||||||||||||||||||||
2021 | 2020 | 2021 | 2020 | 2021 | 2020 | 2021 | 2020 | |||||||||||||||||||||||
Change | % Change | Change | % Change | |||||||||||||||||||||||||||
(dollars in thousands) | ||||||||||||||||||||||||||||||
Revenues | $ | 24,960 | $ | 13,554 | $ | 39,781 | $ | 28,361 | $ | 11,406 | 84 | % | $ | 11,420 | 40 | % | ||||||||||||||
Cost of revenues | 16,937 | 9,030 | 26,704 | 19,743 | 7,907 | 88 | % | 6,961 | 35 | % | ||||||||||||||||||||
Gross profit | 8,023 | 4,524 | 13,077 | 8,618 | 3,499 | 77 | % | 4,459 | 52 | % | ||||||||||||||||||||
Add: | ||||||||||||||||||||||||||||||
Depreciation and amortization | 1,222 | 911 | 2,444 | 1,803 | 311 | 34 | % | 641 | 36 | % | ||||||||||||||||||||
Equipment leasing costs (b) | 4 | 18 | 8 | 42 | (14) | (78) | % | (34) | (81) | % | ||||||||||||||||||||
Stock based compensation | 6 | - | 6 | - | 6 | * | 6 | * | ||||||||||||||||||||||
Adjusted gross profit | $ | 9,255 | $ | 5,453 | $ | 15,535 | $ | 10,463 | 3,802 | 70 | % | 5,072 | 48 | % | ||||||||||||||||
Adjusted gross margin | 37 | % | 40 | % | 39 | % | ||||||||||||||||||||||||
Three Months Ended | Six Months Ended | Three Months Ended | Six Months Ended | |||||||||||||||||||||||||||
2021 | 2020 | 2021 | 2020 | 2021 | 2020 | 2021 | 2020 | |||||||||||||||||||||||
Change $ | Change % | Change $ | Change % | |||||||||||||||||||||||||||
(dollars in thousands) | ||||||||||||||||||||||||||||||
Net loss | $ | (14,458) | $ | (8,163) | $ | (27,053) | $ | (15,380) | $ | (6,295) | 77 | % | $ | (11,673) | 76 | % | ||||||||||||||
Add: | ||||||||||||||||||||||||||||||
Interest expense (c) | 5,124 | 2,836 | 5,298 | 5,616 | 2,288 | 81 | % | (318) | (6) | % | ||||||||||||||||||||
Income tax expense | 17 | 2 | (317) | 3 | 15 | * | (320) | * | ||||||||||||||||||||||
Depreciation and | 2,480 | 1,317 | 4,141 | 2,607 | 1,163 | 88 | % | 1,534 | 59 | % | ||||||||||||||||||||
Stock-based | 4,786 | 148 | 10,644 | 247 | 4,638 | 3,128 | % | 10,397 | 4,209 | % | ||||||||||||||||||||
Gain on contingent shares | (2,192) | - | (5,644) | - | (2,192) | * | (5,644) | * | ||||||||||||||||||||||
Loss on puttable option | - | 96 | - | 105 | (96) | (100) | % | (105) | (100) | % | ||||||||||||||||||||
Gain on change in fair | (2,947) | - | (2,947) | - | (2,947) | * | (2,947) | * | ||||||||||||||||||||||
Integration, acquisition, | 1,772 | 2,130 | 5,909 | 2,503 | (358) | (17) | % | 3,406 | 136 | % | ||||||||||||||||||||
Adjusted EBITDA | $ | (5,418) | $ | (1,634) | $ | (9,969) | $ | (4,299) | (3,784) | 232 | % | (5,670) | 132 | % | ||||||||||||||||
* Percentage not meaningful |
For the Three Months Ended | |||||||||||||
June 30, 2021 | June 30, 2020 | Change $ | Change % | ||||||||||
(dollars in thousands) | |||||||||||||
Selling, general and administrative expenses (1) | $ | 22,479 | $ | 9,753 | $ | 12,726 | 130 | % | |||||
Sales and marketing | 2,397 | 1,446 | 951 | 66 | % | ||||||||
Research and development | 530 | 255 | 275 | 108 | % | ||||||||
Operations | 2,548 | 2,088 | 460 | 22 | % | ||||||||
General and administrative | 17,004 | 5,964 | 11,040 | 185 | % | ||||||||
$ | 22,479 | $ | 9,753 | $ | 12,726 | 130 | % | ||||||
(1) | Selling, general, and administrative expenses include the following expenses for the periods presented: |
Three Months Ended June 30, 2021 | Three Months Ended June 30, 2020 | ||||||||||||||||
Stock-Based | Depreciation and | Integration | Stock-Based | Depreciation | Integration | ||||||||||||
(dollars in thousands) | |||||||||||||||||
Sales and marketing | $ | 73 | $ | — | $ | — | $ | 8 | $ | — | $ | — | |||||
Research and development | 180 | — | — | 33 | — | — | |||||||||||
Operations | 184 | — | — | 21 | — | — | |||||||||||
General and administrative | 4,343 | 1,303 | 1,772 | 86 | 417 | 2,130 | |||||||||||
$ | 4,780 | $ | 1,303 | $ | 1,772 | $ | 148 | $ | 417 | $ | 2,130 | ||||||
For the Three Months Ended | |||||||||||||
June 30, 2021 | June 30, 2020 | Change $ | Change % | ||||||||||
(dollars in thousands) | |||||||||||||
Selling, general and administrative expenses excluding | $ | 14,624 | $ | 7,058 | $ | 7,566 | 107 | % | |||||
Sales and marketing | 2,324 | 1,438 | 886 | 62 | % | ||||||||
Research and development | 350 | 222 | 128 | 58 | % | ||||||||
Operations | 2,364 | 2,067 | 297 | 14 | % | ||||||||
General and administrative | 9,586 | 3,331 | 6,255 | 188 | % | ||||||||
$ | 14,624 | $ | 7,058 | $ | 7,566 | 107 | % | ||||||
For the Six Months Ended | |||||||||||||
June 30, 2021 | June 30, 2020 | Change $ | Change % | ||||||||||
(dollars in thousands) | |||||||||||||
Selling, general and administrative expenses (1) | $ | 43,740 | $ | 18,274 | $ | 25,466 | 139 | % | |||||
Sales and marketing | 4,987 | 2,985 | 2,002 | 67 | % | ||||||||
Research and development | 1,058 | 541 | 517 | 96 | % | ||||||||
Operations | 5,062 | 4,182 | 880 | 21 | % | ||||||||
General and administrative | 32,633 | 10,566 | 22,067 | 209 | % | ||||||||
$ | 43,740 | $ | 18,274 | $ | 25,466 | 139 | % | ||||||
(1) | Selling, general, and administrative expenses include the following expenses for the periods presented: |
Six Months Ended June 30, 2021 | Six Months Ended June 30, 2020 | ||||||||||||||||||
Stock-Based | Depreciation | Integration | Stock-Based | Depreciation | Integration | ||||||||||||||
(dollars in thousands) | |||||||||||||||||||
Sales and marketing | $ | 343 | $ | — | $ | — | $ | 14 | $ | — | $ | — | |||||||
Research and development | 274 | — | — | 41 | — | — | |||||||||||||
Operations | 315 | — | — | 34 | — | — | |||||||||||||
General and administrative | 9,705 | 1,697 | 5,909 | 158 | 815 | 2,503 | |||||||||||||
$ | 10,637 | $ | 1,697 | $ | 5,909 | $ | 247 | $ | 815 | $ | 2,503 | ||||||||
For the Six Months Ended | |||||||||||||
June 30, 2021 | June 30, 2020 | Change $ | Change % | ||||||||||
(dollars in thousands) | |||||||||||||
Selling, general and administrative expenses excluding | $ | 25,497 | $ | 14,709 | $ | 10,788 | 73 | % | |||||
Sales and marketing | 4,644 | 2,971 | 1,673 | 56 | % | ||||||||
Research and development | 784 | 500 | 284 | 57 | % | ||||||||
Operations | 4,747 | 4,148 | 600 | 14 | % | ||||||||
General and administrative | 15,322 | 7,090 | 8,232 | 116 | % | ||||||||
$ | 25,497 | $ | 14,709 | $ | 10,788 | 73 | % | ||||||
Explanation of Non-GAAP Adjustments
(a) Depreciation and amortization consists primarily of depreciation of fixed assets, amortization of capitalized software development costs and amortization of acquisition-related intangible assets, such as customer relationships, non-compete agreements, and trade names acquired in connection with business combinations. While depreciation and amortization are non-cash charges, the assets being depreciated or amortized will often have to be replaced or updated in the future, and these measures do not reflect any cash requirements for these replacements or updates. Additionally, we incur amortization of acquisition-related intangible assets based on the portion of the purchase price allocated to intangible assets and the estimated useful lives of such assets. However, the purchase price allocated to these assets is not necessarily reflective of the cost we would incur to internally develop the intangible asset and we do not believe these charges are reflective of our operating results in the period incurred. We eliminate these non-cash charges from our non-GAAP operating results to facilitate an understanding of our operating and financial performance from period-to-period.
(b) Equipment leasing costs consist of the cost of procuring telemedicine equipment through lease financing. We ceased this practice in the second quarter of 2017. We eliminate these charges from our non-GAAP operating results to facilitate an understanding of our operating and financial performance from period-to-period.
(c) Interest expense consists primarily of interest incurred on our outstanding indebtedness and non-cash interest related to the amortization of debt discount and issuance costs associated with our term loan agreement. We eliminate these cash and non-cash expenses from our non-GAAP operating results to facilitate an understanding of our operating and financial performance from period-to-period within our presentation of adjusted EBITDA. Adjusted EBITDA is widely used by investors to measure a company's operating performance without regard to items, such as interest benefit and expense, income tax benefit and expense, depreciation and amortization, stock-based compensation, and other charges and income. We believe adjusted EBITDA is useful in evaluating our operating performance compared to that of other companies in our industry as this metric generally eliminates the effects of certain items that may vary from company to company for reasons unrelated to overall operating performance.
(d) We incur income tax expenses or benefits that are related to prior periods. We eliminate these expenses from our non-GAAP operating results to facilitate an understanding of our operating and financial performance from period-to-period within our presentation of adjusted EBITDA.
(e) Stock-based compensation expense consists of expenses for stock options and other stock-based awards. Although stock-based compensation is a key incentive offered to our employees, we continue to evaluate our operating and financial performance excluding stock-based compensation expenses. Stock-based compensation expenses will recur in future periods. We evaluate our performance both with and without these measures because stock-based compensation is a non-cash expense and can vary significantly over time based on the timing, size, nature and design of the awards granted, and is influenced in part by certain factors that are generally beyond our control, such as the volatility of the market value of our common stock. In addition, we eliminate stock-based compensation expense from our non-GAAP operating results to facilitate an understanding of our operating and financial performance from period-to-period.
(f) Gain on contingent share issuance liabilities consists of the change in fair value of 1,875,000 shares of our common stock held by HCMC's sponsor and subsequently distributed to permitted transferees and were modified and became subject to forfeiture in connects with the closing of our Merger Transaction, and 350,000 private placement warrants granted to HCMC's sponsor subsequently distributed to its permitted transferees as part of the Merger Transaction. The contingent shares issuance liabilities are revalued at their fair value every reporting period.
(g) Loss on puttable option liabilities consists of changes in the fair value of puttable option liabilities. We eliminate these non-cash expenses from our non-GAAP operating results to facilitate an understanding of our operating and financial performance from period-to-period.
(h) Gain on change in fair value of contingent consideration is the change in fair value of the earnout contingent consideration and the deferred payment in connection with our acquisition of Access Physicians in Q1 2021. The contingent consideration is revalued every reporting period based on the estimation of the likelihood that such contingent consideration will be earned. We eliminate these non-cash activities from our non-GAAP operating results to facilitate an understanding of our operating and financial performance from period-to-period.
(i) Integration, acquisition, transaction and executive severance costs represent the transaction and business integration costs related to our business combination with Healthcare Merger Corp. in Q4 2020 and our acquisition of Access Physicians in Q1 2021. These costs include incremental expenses incurred to affect business combinations such as advisory, legal, accounting, valuation, and other professional or consulting fees, as well as other related incremental executive severance costs. We exclude these costs from our non-GAAP results as they have no direct correlation to the operation of our business, and because we believe that the non-GAAP financial measures excluding these costs provide useful information about our spending trends to facilitate an understanding of our operating and financial performance from period-to-period.
Media Relations:
Lauren Shankman
Trevelino/Keller
lshankman@trevelinokeller.com
Investor Relations:
Steve Rubis
Vice President, Investor Relations
SOC Telemed
P: (214) 681-7991
srubis@soctelemed.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/soc-telemed-reports-second-quarter-2021-financial-and-operating-results-301354702.html
SOURCE SOC Telemed
FAQ
What were SOC Telemed's total consults in Q2 2021?
What was the revenue for SOC Telemed in Q2 2021?
What is the net loss reported by SOC Telemed for Q2 2021?
How did SOC Telemed revise its financial outlook for 2021?
What was the growth rate of SOC Telemed's late-stage pipeline?
